Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01674621 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
A Phase 2 study, sponsored by Radius Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT01674621 is a Phase 2 study that has completed, run by Radius Health. The registered enrollment target is 250 participants.
The verdict
NCT01674621, a Phase 2 study, has completed, sponsored by Radius Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to transdermal placebo and abaloparatide injection for 6 months of treatment.
Interventions
- DRUG Abaloparatide Transdermal (50 mcg)
- DRUG Abaloparatide Transdermal (100 mcg)
- DRUG Abaloparatide Transdermal (150 mcg)
- DRUG Abaloparatide Injection (80 mcg)
- DRUG Abaloparatide Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2012-09-25 |
| Est. Completion | 2013-08-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01674621
The ClinicalTrials.gov registry entry for NCT01674621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radius Health, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Abaloparatide Transdermal (50 mcg) is the first listed.
NCT01674621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01674621 about?
NCT01674621 is a clinical study titled "Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis". To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to transdermal placebo and abaloparatide injection for 6 mont...
What is the current status of trial NCT01674621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2012-09-25. Estimated completion is 2013-08-02.
What interventions are being tested in trial NCT01674621?
The interventions under investigation include: Abaloparatide Transdermal (50 mcg) (DRUG), Abaloparatide Transdermal (100 mcg) (DRUG), Abaloparatide Transdermal (150 mcg) (DRUG), Abaloparatide Injection (80 mcg) (DRUG), Abaloparatide Placebo (DRUG).
Who is sponsoring clinical trial NCT01674621?
This trial is sponsored by Radius Health, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.